Cite
First-in-human safety, tolerability, and pharmacokinetics of SY-007, a prolonged action neuroprotective drug for ischemic stroke, in healthy Chinese subjects.
MLA
Wang, Zhenlei, et al. “First-in-Human Safety, Tolerability, and Pharmacokinetics of SY-007, a Prolonged Action Neuroprotective Drug for Ischemic Stroke, in Healthy Chinese Subjects.” European Journal of Pharmaceutical Sciences, vol. 170, Mar. 2022, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ejps.2021.106104.
APA
Wang, Z., Jin, Y., Shen, Q., Zhuo, L., Liu, R., Di, X., Xiang, L., Zhang, G., Wang, Y., Wang, Y., & Zheng, L. (2022). First-in-human safety, tolerability, and pharmacokinetics of SY-007, a prolonged action neuroprotective drug for ischemic stroke, in healthy Chinese subjects. European Journal of Pharmaceutical Sciences, 170, N.PAG. https://doi.org/10.1016/j.ejps.2021.106104
Chicago
Wang, Zhenlei, Ying Jin, Qi Shen, Lang Zhuo, Runhan Liu, Xiangjie Di, Lisha Xiang, et al. 2022. “First-in-Human Safety, Tolerability, and Pharmacokinetics of SY-007, a Prolonged Action Neuroprotective Drug for Ischemic Stroke, in Healthy Chinese Subjects.” European Journal of Pharmaceutical Sciences 170 (March): N.PAG. doi:10.1016/j.ejps.2021.106104.